ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT

Key Points

• ABN Amro Investment Solutions increased its Abbott Laboratories stake by 21.1% in the second quarter, bringing its holdings to 111,702 shares valued at approximately $10.1 million. Institutional investors collectively own 75.18% of Abbott stock.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 EPS and $12.59 billion in revenue, with revenue up 13% year over year. The company maintained 2026 EPS guidance of $5.45–$5.60 and pays a $0.63 quarterly dividend, yielding about 2.2%.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average $118.67 price target, while Abbott’s diabetes-care and medical-device partnerships support growth. However, approximately $670 million in infant-formula litigation settlements, alongside a separate $495 million case resolution, adds financial and legal risk.

ABN Amro Investment Solutions raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 21.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 111,702 shares of the healthcare product maker's stock after buying an additional 19,480 shares during the quarter. ABN Amro Investment Solutions' holdings in Abbott Laboratories were worth $10,136,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ABT. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter worth $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $114.16 on Friday. The stock's fifty day simple moving average is $99.51 and its 200 day simple moving average is $99.93. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $197.54 billion, a price-to-earnings ratio of 36.94, a P/E/G ratio of 2.21 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Piper Sandler reissued an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, BTIG Research increased their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $118.67.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now integrated into MiniMed’s Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott’s presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott’s cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott’s Medical Devices Growth Catalyst
• Neutral Sentiment: Recent commentary remains broadly constructive on Abbott’s long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement
• Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source